Myriad Genetics, Inc. (MYGN) Market Cap

Myriad Genetics, Inc. (MYGN) has a market capitalization of $429.7M, based on the latest available market data.

Financials updated after earnings reported 2025-12-31.

Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: 2700
Exchange: NASDAQ Global Select
Headquarters: Salt Lake City, UT, US
Website: https://myriad.com

Loading company profile...

Expand full investment commentary ▼

📘 MYRIAD GENETICS INC (MYGN) — Investment Overview

🧩 Business Model Overview

Myriad Genetics Inc. (MYGN) operates as a leader in the genetic testing and precision medicine industry. The company focuses on developing and providing molecular diagnostic tests that assess an individual's risk of developing disease, predict disease progression, and guide personalized medical treatment based on genetic insights. Myriad’s solutions span several medical specialties, such as oncology, women’s health, neuroscience, and pharmacogenomics. The company’s business model is based on the integration of advanced molecular diagnostics with an ongoing commitment to research and development, a direct engagement sales force, partnerships with health systems, and a portfolio-driven approach that emphasizes both innovation and clinical utility.

💰 Revenue Streams & Monetisation Model

Myriad derives revenue primarily through the sale of proprietary genetic testing services to physicians, healthcare systems, and patients. The key revenue streams can be categorized as follows: - **Diagnostic Testing Services:** Fees generated from clinical laboratories processing patient samples and delivering certified genetic test results to clinicians. - **Patient-Paid Fees and Insurance Reimbursements:** The majority of revenues come from third-party payors, including private insurers, Medicare, and Medicaid, with some direct billing to patients, depending on insurance coverage and test type. - **Collaborative Research and Licensing:** Secondary revenues arise from research partnerships, collaborative agreements with biopharmaceutical firms, and licensing of proprietary biomarker technologies. - **Data Insights and Software Solutions:** Emerging monetization includes leveraging accumulated genomics data and proprietary analytics platforms (such as Precise Oncology Solutions) offered to providers and pharma partners, though this segment remains a minority of revenues. Monetization is supported by a broad test menu, with frequent use in oncology (hereditary cancer, breast, ovarian, and prostate cancer risk testing), reproductive health (carrier screening, prenatal testing), mental health (pharmacogenetic screening), and rare disease assessments.

🧠 Competitive Advantages & Market Positioning

Myriad Genetics has cultivated strong brand recognition, particularly among oncologists and women’s health practitioners. The company’s advantages include: - **Proprietary IP Portfolio:** MYGN holds a significant portfolio of proprietary genetic markers, algorithms, and software necessary for test delivery, interpretation, and reporting. - **Clinical Validation and Guideline Inclusion:** Multiple Myriad tests are supported by peer-reviewed clinical data and have secured inclusion in professional society guidelines, leading to regular usage and insurance reimbursement. - **Robust Commercial Infrastructure:** The company maintains a national sales force and longstanding relationships with key health systems, providers, and payors. - **Scale and Data Advantage:** With millions of samples processed over decades, Myriad’s data repository enables refinement of risk algorithms and offers differentiation in test accuracy, variant classification, and report utility. - **Product Innovation:** The firm continues to invest in test development, extending competitive edge into areas such as polygenic risk scoring, comprehensive genomic profiling, and multi-analyte diagnostics. Competition is intense, with key rivals such as Invitae, Natera, Exact Sciences, and LabCorp, yet Myriad’s heritage, clinical credibility, and payer access yield defensible market share in core product segments.

🚀 Multi-Year Growth Drivers

Several secular trends support a robust, multi-year growth outlook for Myriad Genetics: - **Advancing Precision Medicine Adoption:** Healthcare’s shift toward personalized, genomically informed care is expanding demand for genetic diagnostics across oncology, reproductive health, and mental health. - **Expanded Insurance Coverage and Utilization:** Improved clinical guidelines and payer awareness are driving higher test utilization and greater reimbursement for broader panels and emerging indications. - **Product Portfolio Expansion:** Introduction of next-generation sequencing panels, companion diagnostics, and AI-enhanced risk prediction tools increases average revenue per test and opens adjacent market opportunities. - **International Expansion:** Uptake of genetic testing is rising globally; Myriad has opportunities to leverage partnerships and direct market entry to capture international growth. - **Partnerships with Pharma and Digital Health:** Collaborations for biomarker-driven drug development, clinical trial enrollment, and the licensing of analytic platforms provide long-term revenue diversity and scalability. - **Population Health Initiatives:** System-level genomic screening for health systems and payors is emerging, and Myriad’s scale and data infrastructure enable leadership as population genomics matures.

⚠ Risk Factors to Monitor

Despite structural tailwinds, the Myriad Genetics investment case faces prominent risks: - **Pricing and Reimbursement Pressures:** Genetic test pricing is subject to ongoing scrutiny; reimbursement denials, coverage limits, or reductions can directly impact revenues and margins. - **Regulatory Environment:** Changes in regulatory oversight (FDA or CMS) around laboratory-developed tests (LDTs), genetic data privacy, and consent laws may increase compliance costs or restrict offerings. - **Pace of Innovation and Competition:** Rapid technological innovation from competitors could diminish demand for legacy tests, compress margins, or necessitate higher R&D outlays to maintain relevance. - **Operational and Execution Risks:** Integration of acquisitions, management of laboratory operations, and scale-up of new offerings present operational complexity. - **Legal and IP Challenges:** Patent expirations or litigation related to genetic markers and testing algorithms could erode barriers to entry or result in costly settlements. - **Data Security and Privacy:** As genomic data becomes a more strategic asset, breaches or cyber threats present reputational and regulatory liabilities.

📊 Valuation & Market View

The valuation of Myriad Genetics is typically characterized by growth and innovation-oriented multiples, often benchmarked against a select group of genomic diagnostics peers. Investors assess the company based on a blend of revenue growth trajectory, test volume growth, gross margin trends, product pipeline strength, and the company’s ability to sustainably expand both its top and bottom lines. Key valuation drivers include: - **Revenue Growth Rates vs. Peer Group:** Persistent above-market growth in diagnostic volumes and revenues is a critical expectation. - **Margin Expansion:** Operating leverage from scale, automation, and payer contracting can contribute to profitability and valuation re-rating. - **R&D Productivity:** Delivery of new, clinically validated tests and successful entry into emerging clinical domains are factored into forward-looking multiples. - **Strategic Optionality:** The addressable market for genomics remains expansive, and any successful extension into digital health, pharmaceutical services, or international markets is considered a premium opportunity. The investment community continually weighs these factors against inherent reimbursement volatility, regulatory shifts, and competitive threats. The stock price often reflects both the company’s innovation pipeline and sentiment around the future monetization of the genomic diagnostic landscape.

🔍 Investment Takeaway

Myriad Genetics presents a compelling, long-term exposure to the intersection of genomics and precision medicine. The company’s entrenched market position, diverse test portfolio, and data-enabled differentiation provide core strengths amid a rapidly evolving healthcare landscape. Success depends on continued innovation, scaling of new products, and adept navigation of reimbursement and regulatory headwinds. For investors seeking growth in healthcare diagnostics, MYGN offers both opportunity and complexity—requiring diligent monitoring of industry dynamics, competitive developments, and management execution.

⚠ AI-generated — informational only. Validate using filings before investing.

SEC Filings

Related Companies in Healthcare

LAB logo

STANDARD BIOTOOLS INC (LAB)

Healthcare

$0.43B

EBS logo

EMERGENT BIOSOLUTIONS INC (EBS)

Healthcare

$0.43B

LENZ logo

LENZ THERAPEUTICS INC (LENZ)

Healthcare

$0.42B

TECX logo

TECTONIC THERAPEUTIC INC (TECX)

Healthcare

$0.44B

UPB logo

UPSTREAM BIO INC (UPB)

Healthcare

$0.42B

DMAC logo

DIAMEDICA THERAPEUTICS INC (DMAC)

Healthcare

$0.41B